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Abstract
Rothmund-Thomson syndrome (RTS) is a genodermatosis presenting with a characteristic facial rash (poikiloderma)
associated with short stature, sparse scalp hair, sparse or absent eyelashes and/or eyebrows, juvenile cataracts, ske-
letal abnormalities, radial ray defects, premature aging and a predisposition to cancer. The prevalence is unknown
but around 300 cases have been reported in the literature so far. The diagnostic hallmark is facial erythema, which
spreads to the extremities but spares the trunk, and which manifests itself within the first year and then develops
into poikiloderma. Two clinical subforms of RTS have been defined: RTSI characterised by poikiloderma, ectodermal
dysplasia and juvenile cataracts, and RTSII characterised by poikiloderma, congenital bone defects and an increased
risk of osteosarcoma in childhood and skin cancer later in life. The skeletal abnormalities may be overt (frontal bos-
sing, saddle nose and congenital radial ray defects), and/or subtle (visible only by radiographic analysis). Gastroin-
testinal, respiratory and haematological signs have been reported in a few patients. RTS is transmitted in an
autosomal recessive manner and is genetically heterogeneous: RTSII is caused by homozygous or compound het-
erozygous mutations in the RECQL4 helicase gene (detected in 60-65% of RTS patients), whereas the aetiology in
RTSI remains unknown. Diagnosis is based on clinical findings (primarily on the age of onset, spreading and
appearance of the poikiloderma) and molecular analysis for RECQL4 mutations. Missense mutations are rare, while
frameshift, nonsense mutations and splice-site mutations prevail. A fully informative test requires transcript analysis
not to overlook intronic deletions causing missplicing. The diagnosis of RTS should be considered in all patients
with osteosarcoma, particularly if associated with skin changes. The differential diagnosis should include other
causes of childhood poikiloderma (including dyskeratosis congenita, Kindler syndrome and Poikiloderma with Neu-
tropaenia), other rare genodermatoses with prominent telangiectasias (including Bloom syndrome, Werner syn-
drome and Ataxia-telangiectasia) and the allelic disorders, RAPADILINO syndrome and Baller-Gerold syndrome,
which also share some clinical features. A few mutations recur in all three RECQL4 diseases. Genetic counselling
should be provided for RTS patients and their families, together with a recommendation for cancer surveillance for
all patients with RTSII. Patients should be managed by a multidisciplinary team and offered long term follow-up.
Treatment includes the use of pulsed dye laser photocoagulation to improve the telangiectatic component of the
rash, surgical removal of the cataracts and standard treatment for individuals who develop cancer. Although some
clinical signs suggest precocious aging, life expectancy is not impaired in RTS patients if they do not develop can-
cer. Outcomes in patients with osteosarcoma are similar in RTS and non-RTS patients, with a five-year survival rate
of 60-70%. The sensitivity of RTS cells to genotoxic agents exploiting cells with a known RECQL4 status is being
elucidated and is aimed at optimizing the chemotherapeutic regimen for osteosarcoma.
Disease names and synonyms
Rothmund-Thomson syndrome (RTS) (OMIM#268400)
Poikiloderma atrophicans and cataract
Definition
RTS is an autosomal recessive genodermatosis present-
ing in infancy with a characteristic facial rash
(poikiloderma), the diagnostic hallmark, and heteroge-
neous clinical features including short stature, sparse
scalp hair, sparse or absent eyelashes and/or eyebrows,
juvenile cataracts, skeletal abnormalities, radial ray
defects, premature aging and a predisposition to osteo-
sarcoma, a malignant tumour originating in bone.
RTS was originally described in 1868 by the German
ophthalmologist Rothmund who observed poikiloderma,
growth retardation and rapidly progressive bilateral juve-
nile cataracts in 10 children in a Bavarian village [1]. In* Correspondence: lidia.larizza@unimi.it1Department of Medicine, Surgery and Dentistry, University of Milan, Italy
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1936, the English dermatologist Thomson reported three
similar patients with “Poikiloderma congenitale” and
growth retardation who displayed skeletal defects,
including bilateral thumb aplasia and hypoplastic radii
and ulnae, but no cataracts [2]. The eponym Rothmund-
Thomson syndrome was coined by Taylor in 1957 to
describe a group of patients with the above-mentioned
disorders [3]. At present the rationale for such grouping
awaits further knowledge on the molecular basis of the
syndrome.
Following the association in 1999 of a subset of RTS
cases with homozygous or compound heterozygous
mutations in the human helicase gene RECQL4 [4], two
forms of RTS have emerged based on clinical and mole-
cular analysis: type I RTS, characterised by poikilo-
derma, ectodermal dysplasia and juvenile cataracts,
negative for the RECQL4-mutation scan and type II
RTS, with poikiloderma, congenital bone defects and an
increased risk of osteosarcoma related to deleterious
RECQL4 mutations [5]. Whether RTS I and II represent
distinct syndromes with overlapping clinical signs or
intersecting nosological entities involving genes acting
on the same pathway, remains to be assessed.
Epidemiology
RTS is a very rare disease and reliable data on its preva-
lence are not available. To date, approximately 300
patients have been recorded in the medical literature
[6-8]. Due to the highly variable clinical spectrum [9],
which brings together patients with shared and unique
developmental defects, patients who display an atypical/
borderline clinical presentation may be overlooked. Con-
sistent with autosomal recessive transmission, most
patients appear as isolated cases but a few siblings,
mostly from consanguineous families or from small
close communities, have been reported [1,2,4,5,10,6-16].
The carrier frequency is unknown.
Whether RTS has a predilection for one sex over the
other is unclear. An equal female-to-male ratio, a female
predominance (1.4:1), and a male predominance (2:1)
have all been reported in various case series [17]
RTS has been described in all ethnic groups: no foun-
der effect has been detected in a specific population,
although certain mutations may exist within defined
populations.
Clinical description
Patients may display few or many of the associated clini-
cal features specified below, depending on their preva-
lence in the reported series of cases and the
developmental origin of the affected tissue. The severity
of each sign can also vary. The clinical suspicion of RTS
is usually raised by the dermatologist because the ecto-
dermal compartment is affected in most RTS patients.
The first signs are those that affect the skin, hair, nails
and teeth, which belong to the epidermis and the dermis
and are of ectodermal and mesodermal origin respec-
tively. Teeth, like hair and nails are epithelial appen-
dages and their malformations are classified as
cutaneous rather than as extracutaneous manifestations
[18].
Growth delay and the resulting short stature is the
second major clinical sign of RTS. The skeletal system is
of extraordinary relevance to the pathogenesis of the
disease, as shown by congenital skeletal defects in a con-
sistent subset of patients and by more subtle anomalies,
visualised on X-rays in the majority of the cases. Ocular
lesions are currently considered a minor sign, possibly
specific to a subset of RTS patients: although initially
the prevalence of cataracts was reported to be as high as
50% in some series [6], it was subsequently found to be
much lower [19]. Gastrointestinal, haematological and
respiratory anomalies/clinical signs have been recorded
sporadically. Cancer predisposition is a central sign in
the development of the disease. It is not surprising that
the most frequent tumour types, osteosarcoma (gener-
ally in childhood, or adolescence) and spinocellular car-
cinoma of the skin (in adults), develop in the cellular
compartments most severely affected by the disease.
Skin
The main clinical diagnostic hallmark of the syndrome
is the cutaneous rash, which usually develops between
the age of three and six months as erythema, swelling
and blistering on the face (Fig. 1A), which subsequently
spreads to the extremities (first on the extensor, then on
the flexor surfaces) and to the buttocks. The trunk and
abdomen are usually spared (Fig. 1D, E). The rash devel-
ops over time from the acute to the chronic phase with
telangiectasic lesions, reticulated areas of depigmenta-
tion, hyperpigmentation and punctate atrophy. These
changes, described as poikiloderma (Fig. 1B, C, D) [20]
persist throughout life. Café au lait spots may develop
later. Worsening of the erythema following sun expo-
sure is experienced by some patients. Although 89% of
the cases present within the first two years of life, late
onset of poikilodermatous changes has been reported to
occur. However, no mutation assay has been performed
in these cases to suggest that they may be variant forms
of RTS [21]. Poikiloderma occurs in a number of geno-
dermatoses and other syndromes but with a subtly dif-
ferent pattern (see Differential Diagnosis). The accurate
recognition of the onset, development and stabilisation
of poikiloderma is thus necessary to establish the clinical
suspicion of RTS.
A few subjects have early ageing of the skin. Palmo-
plantar hyperkeratotic lesions occur in about one-third
of individuals. The overall histological picture is diffuse
lamellar hyperkeratosis.
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Calcinosis cutis and porokeratosis are uncommon but
have been reported [22].
Hair
Sparse, brittle, thin or absent scalp hair and sparse hair
on eyelashes and/or eyebrows were observed in 50% and
73% of the patients, respectively (Fig. 1A, B, D), in a
cohort of 41 RTS patients evaluated in detail by Wang
[19]. Beard, pubic and axillary hair may be almost
absent and partial or total alopecia may develop (Fig.
1B).
Nails
Dystrophic or poorly formed nails are common. Pachyo-
nichia is also a frequent sign.
Teeth
Dental abnormalities associated with RTS were first
noticed by Rothmund in his original article [1]. They
include a wide variety of malformations such as micro-
dontia, rudimentary or hypoplastic teeth, multiple and
unusual crown formations, and disorders of dental
breakthrough. Structural defects of connective tissue
have been shown by electron microscopy on a gingival
biopsy specimen from one case [23]. Dental
abnormalities affecting the complete permanent denti-
tion, which were detected by radiographic examination,
have been described in detail in an adult male patient
with RTS. He had abnormally short roots, mainly of the
maxillary teeth, and his third molars had only partially
erupted [18]. An increased incidence of caries has been
observed in RTS patients [24].
The overall incidence of dental abnormalities has been
estimated at between 27% and 59% of the cases [6,9,18].
Growth
Low birth weight, slow weight gain and linear growth
deficiency are present in at least two-thirds of RTS
patients [19]. RTS patients are proportionately small (for
weight and height) without asymmetry. Short stature is
defined as -2SD (standard deviation) score. Most
patients with the characteristic short stature have nor-
mal growth hormone levels, but isolated cases with
growth hormone deficiency have been described
[9,25,26].
Neurocognitive development
Neurologic cognitive milestones and intelligence are
usually normal. Mental retardation was reported in six
Figure 1 Panel showing some clinical features of the RTS syndrome. A) Chronic phase of cheek poikiloderma (4-year-old girl).
B) Poikiloderma with alopecia (21-year-old boy). C) Poikiloderma. D) Poikiloderma sparing the trunk (courtesy of Professor M. Paradisi, Rome).
E) Photo distributed poikiloderma and valgism of the knees. F) Thumb aplasia (patient B). G) Bone defect seen by X-Rays: cystic-like destructive
lesion of the humerus (distal epiphysis) without apparent solution of continuity of the cortical bone (patient E).
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out of 202 patients [6]. Delayed speech development was
found in a few cases [27]; Nathanson et al. [28] reported
a case of poikiloderma congenitale with short stature
and mental retardation. More recently Gelaw and coau-
thors [29] suggested that the accelerated cerebral atro-
phy, which was demonstrated in one case with RTS,
Klippel-Feil syndrome and osteosarcoma, may be the
underlying cause of mental retardation seen in a subset
of patients with RTS.
Deafness
Sensorineural deafness has been reported in one patient
[30].
Skeleton
In a review of the world literature [5,6], 68% of the
patients were found to display skeletal anomalies,
including frontal bossing, saddle nose and abnormalities
of the long bones. The latter often appear as congenital
radial ray defects, ranging from absence of one or both
radii to short dysmorphic ulnae, absent or hypoplastic
thumbs (Fig. 1F), hypoplasia/agenesis of the patella, syn-
dactyly and diffuse or localised osteoporosis. In the clin-
ical review of Wang, 75% of the patients, who
underwent radiographic skeletal surveys, were found to
have skeletal abnormalities that could not have been
detected by clinical examination alone [19]. This percen-
tage has been recently confirmed by a radiographic sur-
vey of 28 RTS patients who had undergone the RECQL4
mutation test [31]. The most common anomalies were
abnormal metaphyseal trabeculation, brachymesopha-
langy, thumb aplasia or hypoplasia, osteopaenia, destruc-
tive bone lesions (Fig. 1G), dislocation of the radial
head, radial aplasia or hypoplasia, and patellar ossifica-
tion defects. Genotype-phenotype analysis showed that
all patients with the RECQL4 mutation had skeletal
abnormalities, further confirming that the RECQL4
mutational status may be indicative of increased risk of
osteosarcoma.
Ocular lesions
Bilateral cataracts, which are rapid in onset (usually 2 to
3 months) and are subcapsular, develop in the early
years of life and represent the most frequent ocular
sign, though they are not as common as previously indi-
cated. Some affected patients go completely blind later
in life. Other ocular abnormalities include exophthal-
mos, corneal atrophy/scleralization, congenital bilateral
glaucoma [28], retinal atrophy/coloboma, strabismus,
photophobia and blue sclerae. Iris dysgenesis has been
reported in two instances [11,22,32].
Gastrointestinal system
Oesophageal or pyloric stenosis, anal atresia, annular pan-
creas and rectovaginal fistula have been described [33].
Feeding problems may be encountered in infancy, with
some patients requiring tube feeding. Gastrointestinal
disturbances that manifest as chronic emesis and diar-
rhoea usually resolve in early childhood [26].
Respiratory system
Lower respiratory tract infections have been rarely
reported in patients with RTS [34]. Bronchiectasis was
described in an RTS patient who had died of acute mye-
loblastic leukaemia [14]. Localised bronchiectasis with
recurrent pneumonia that had developed without neu-
tropaenia has been recently described in two cases of
RTS [35]. Characterisation of RECQL4 mutations in one
of the two patients supports the view that bronchiectasis
is likely to be a novel feature of this rare syndrome [35].
Haematological signs
Progressive leukopaenia and chronic microcytic hypo-
chromic anaemia requiring transfusion have been
reported [14,27]. Malignant haematological abnormal-
ities ranging from myelodysplasia to aplastic anaemia
and leukaemia have been identified [14,36-39].
Cancer
A detailed review of the published work reporting on
RTS patients who developed at least one neoplasm out-
lines the spectrum and age of onset of cancers to which
the patients are predisposed [40]. Osteosarcoma occurs
in childhood (mean age of onset: 14 years) whereas
cutaneous epithelial neoplasms (squamous cell carci-
noma, basal cell carcinoma and Bowen’s disease) occur
later (mean age of onset: 34.4 years). Both types of can-
cer develop at a younger age than would be normally
expected. The estimated prevalences of osteosarcoma
and skin cancer in RTS are 30% and 5%, respectively
[19].
The clustering of the two main cancer types can be
seen in the histograms in Fig. 2, which shows the abso-
lute number of tumours described in RTS patients
(cases of secondary tumours, where the histological sub-
type is the same as for the first, have been omitted).
Among mesenchymal tumours other than isolated
osteosarcoma (OS), which represents the most frequent
tumour, malignant fibrous histiocytoma (MFH) has been
reported in more than one case. Squamous cell carci-
noma (SCC) is the most common epithelial tumour. As
far as haematological tumours are concerned, myelodys-
plasia has been reported in three cases [36,38,39].
Tumours that have been described only once are also
included in Fig. 2[40,41].
Isolated osteosarcoma (OS) in RTS patients shows
clinical features similar to those in patients with spora-
dic OS; for example the site of tumour development
(most often the femur and the tibia) and the histological
subtype (mainly osteoblastic). However, as in most can-
cer predisposing syndromes, the age of onset of OS in
RTS patients is earlier than in the sporadic counterpart
(14 vs. 17 years).
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The abnormality in metaphyseal trabeculation in RTS
patients, often observed on X-rays, has been considered
intriguing as most osteosarcomas tend to originate in
the metaphyses [31].
Besides the isolated osteosarcoma (OS), seven cases of
multicentric OS (OSMC) have been reported [19,42-44].
Osteosarcoma is usually defined as multicentric if the
tumour occurs at two or more sites in a patient in the
absence of pulmonary metastases. A multicentric osteosar-
coma is synchronous if more than one lesion is found at
presentation and metachronous if development of appar-
ently new tumour(s) is detected at a new site [45]. Consid-
ering this, three additional cases in which second primary
osteosarcoma lesions have been described, apparently
without pulmonary metastasis, may also be included as
OSMC [9,46-48], making a total of ten cases. It has been
reported that the incidence of multicentric disease asso-
ciated with sporadic osteosarcoma ranges between 0.4%
and 10% of all cases of osteosarcoma [49]. In comparison
to this incidence in isolated OS in RTS, the proportion of
OSMC is higher: 17.9 to 25.6%, based on cases that were
not definitely assessed (overall 32 cases) [16,40]. This sug-
gests an increased risk of OSMC in this syndrome. Similar
considerations have been obtained from the evaluation of
the incidence of metachronous OS in a group of twelve
patients with OS [50].
Indeed, a notable proportion of RTS tumour carriers
developed more than one tumour of the same or
different type, showing that this is the main characteris-
tic of a cancer predisposition syndrome. This is particu-
larly true for a few patients who showed a very high
frequency of recurrence of the disease. Significant exam-
ples are a patient with an adnexal skin tumour and
malignant eccrine poroma, who developed eleven basal
cell carcinomas [51] and another patient who developed
seven skin tumours [40].
There is no evidence for increased cancer risk in the
obligate heterozygous parents of RTS cases.
Aetiopathogenesis
Type II RTS, characterised by poikiloderma and skeletal
defects is caused by homozygous or compound hetero-
zygous mutations in the RECQL4 (also named RECQ4)
helicase gene [4]. Type I RTS, characterised by poikilo-
derma and juvenile cataracts is negative for the RECQL4
mutation and is one (or a set) of orphan Mendelian dis-
ease(s), for which the responsible gene(s) is (are) inten-
sively sought but has (have) not yet been found. The
RECQL4 gene, located at chromosome 8q24.3 [52],
spans 21 exons [53] and its expression is regulated by a
housekeeping promoter containing specific binding sites
for several important transcription factors: SP1, AP1,
AP2CRE and PAE3. It encodes a 133-kDa protein of
1208 aminoacids, RECQ protein-Like 4 (RECQL4;
OMIM #603780), i.e. the ATP-dependent DNA helicase
Q4, which contains the conserved DNA helicase domain
homologous to the Escherichia coli RecQ helicase [54].
There are at least five distinct RECQ helicases in man
that function at the interface of DNA replication,
recombination and repair [55,56]. The RECQ helicases
have received considerable attention during recent years
due to their link to premature aging and cancer suscept-
ibility syndromes. Mutations in three of these helicase
genes, RECQ2 (BLM), RECQ3 (WRN) and RECQL4,
result in the rare autosomal recessive disorders of
Bloom, Werner and RTS, which share the general char-
acteristics of genomic instability and cancer predisposi-
tion. However, each syndrome possesses unique clinical,
cellular and genetic features that highlight the non-over-
lapping roles of the respective genes in the maintenance
of genome integrity.
RECQL4 plays a role in a DNA-dependent ATPase
activity and in single-stranded DNA annealing activity,
but its helicase activity was doubtful [57,58] and as such
RECQL4 appeared to be distinct from all other mem-
bers of the RECQ helicase family. It has been demon-
strated only recently that RECQL4 is not the only
helicase-dead member of the RecQ family as two dis-
tinct regions of the protein, the conserved helicase motif
and the N-terminal domain, each independently pro-
mote ATP-dependent DNA unwinding [59]. Localisation
of the protein has been shown to be both nuclear and
Figure 2 Absolute number of tumours developed by RTS
patients (X axis) grouped by the tissue of origin for each
tumour type (Y axis): Among mesenchymal tumours,
osteosarcoma (OS) is the most frequent. Several cases of
multicentric osteosarcoma (OSMC) have been described, while
malignant fibrous histiocytoma (MFH) has been reported in two
cases. Squamous cell carcinoma (SCC) is the most frequent
cutaneous epithelial tumour followed by basal cell carcinoma (BCC)
and Bowen’s disease (BD). Myelodysplasia has been reported in
three cases (MD). Reports of single cases: fibrosarcoma* (FS),
verrucous carcinoma (VC), Hodgkin’s “sarcoma” (HS), acute myeloid
leukaemia (AML), nasopharyngeal non-Hodgkin’s lymphoma*
(NPhNHL). The group other consists of single cases of gastric
carcinoma, malignant eccrine poroma *, parathyroid adenoma *,
amelanotic melanoma (41) (*all these were reported as a second
neoplasia).
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cytoplasmic [57]: nuclear localisation and retention
domains are amino-terminal, unlike other RecQ proteins
which show carboxyl-terminal nuclear localisation sig-
nals [60]. A cumulative set of data suggest that RECQL4
has roles in several different important cellular pathways
[61]. In HeLa cells, the RECQL4 protein forms a stable
complex with the ubiquitin ligases, UBR1 and UBR2,
which are involved in the N-end rule pathway shown to
be essential for correct chromosome segregation and
apoptosis [57,62]. The RECQL4 protein is significantly
expressed in the S-phase of the cell cycle, suggesting a
role in DNA replication [63]. Indeed, RECQL4 has been
shown in a Xenopus model to be important for initiation
of DNA replication with its N-terminus being required
for the recruitment of DNA polymerase a and its load-
ing onto chromatin [64,65]. The implication of RECQL4
in replication initiation and cell growth has been
demonstrated by mouse models showing that disruption
of exons 5-8 (corresponding to the N-terminus
upstream of the conserved helicase domain) results in
embryonic lethality [66], whereas mice with deletion of
either the single exon 13 or exons 9-13 (corresponding
to helicase domain) are viable [67,68]. The possible
involvement of RECQL4 in the repair of DNA double-
strand breaks (DSB) has been demonstrated by the coin-
cidence of RECQL4 nuclear foci with the foci formed by
RAD51, a crucial protein which functions in homolo-
gous recombination of DNA DSB [69], as well as by the
sensitivity of fibroblasts from RTS patients to ionizing
radiation [6] and by the participation of RECQL4 in
DSB repair in Xenopus egg extracts [70]. RECQL4 inter-
acts with poly(ADP-ribose) polymerase-1 (PARP-1),
which is involved in a competing end-joining pathway
of DSB repair [71], in transcriptional regulation and in
base excision repair (BER) [72]. This suggests that
RECQL4 may act in these pathways or in a combination
of these pathways. It has been reported that RECQL4
plays a role in oxidative stress and its amount increases
in the nucleolus after treatment of cells with agents that
induce reactive oxygen species (ROS) [73]. A defect in
responding to ROS might explain the development of
premature aging in RTS, as one of the hallmarks of
aging is the accumulation of reactive oxygen species.
RECQL4-deficient fibroblasts are hypersensitive to
hydrogen peroxide-induced oxidative stress and show
decreased cell proliferation and a reduction in DNA
synthesis [74]. A role of RECQL4 in the repair of ultra-
violet (UV)-induced DNA damage in human cells,
through interaction with nucleotide excision repair fac-
tor Xeroderma Pigmentosum Group A (XPA), has been
recently demonstrated [75].
Given the multiple roles of RECQL4 in DNA metabo-
lism, it is likely in RTS patients with RECQL4 mutations
that defective DNA replication, enhanced oxidant
sensitivity and unrepaired DNA lesions would lead to
sustained genomic instability. It has been noted that the
function of RECQL4 may be especially important in a
few proliferating tissues, such as developing bone and
skin, as defects in RTS patients mainly affect these tis-
sues [74]. Genotype-phenotype analysis shows that RTS
patients with RECQL4 mutations are at a significantly
higher risk of developing osteosarcoma as compared to
RTS patients without RECQL4 mutations [5,8]. Indeed,
at the cellular level, defects in RECQL4 manifest them-
selves as both numerical (mosaic trisomies) and struc-
tural (high frequency of rearrangements, particularly
isochromosomes) chromosomal instability (CIN) and it
is conceivable that accumulation of CIN can drive pro-
genitor cells of sensitive cell lineages towards neoplastic
transformation.
Mutations in the RECQL4 gene have been associated
with two additional recessive disorders: RAPADILINO
(Radial hypoplasia, Patella hypoplasia and cleft or
Arched palate, DIarrhoea and dislocated joints, Little
size and limb malformation, slender Nose and nOrmal
intelligence), mainly observed in Finland [76] and Bal-
ler-Gerold syndrome (BGS), which is characterised by
radial hypoplasia and craniosynostosis [77-79]. Although
the three syndromes share some clinical features (e.g.
short stature and radial ray abnormalities) there are also
syndrome-specific features [80]. For example, cataracts
are seen only in RTS, joint dislocation and patellar
hypoplasia are seen only in RAPADILINO and craniosy-
nostosis only in BGS.
To date, 56 different mutations in the RECQL4 gene
have been identified, 39 of which are in RTS patients
(see the comprehensive list provided by Siitonen [81] to
which only a few mutations need to be added)
[16,35,82]. The mutations found in all the three
RECQL4 diseases are summarised in Fig. 3. The types of
observed mutations are: i) nonsense mutations that
change an aminoacid to a stop codon and lead to termi-
nation of protein translation; ii) insertions and/or dele-
tions, which lead to reading frameshift and subsequent
termination of protein translation; iii) mis-splicing
alterations including substitutions at canonical splice
junctions or at splice site consensus sequences that
cause the skipping of exons and a downstream frame-
shift and subtle intronic deletions, which reduce intron
size below the threshold (<80 bp) required for correct
splicing [83-85] and iv) missense mutations that cause
an aminoacid change in the protein. Most of the muta-
tions identified in RTS are nonsense or frameshift muta-
tions, which destabilise the mature mRNA through
nonsense mediated-decay. Splice-site or missense muta-
tions are usually present in combination with the former
mutations. Splicing mutations are quite common: it has
been suggested that both the G-C rich minisatellite
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flanking the 3’ splice site of IVS12 in the helicase
domain of the RECQL4 gene and exonic SNPs (Single
Nucleotide Polymorphisms) belonging to high-score
motifs for SR proteins may play a role in RECQL4
mRMA mis-splicing [86]. Splicing mutations also
include deep intronic deletions, cryptic mutations identi-
fiable only by RNA analysis, the harmful effect of which
depends on the genomic structure of the RECQL4 gene.
Indeed, 13 of the 21 introns of the RECQL4 gene are
<100 bp and fortuitous multibase deletions make them
unspliced, implicating intron-size constraint as a muta-
tional mechanism in RTS [83]. These mis-splicing muta-
tions are generally found in a homozygous state.
There are a few recurrent mutations; the geographical
distribution or clustering of the most significant ones is
shown in Fig. 4. It is not surprising that the most com-
mon exon 9 c.1573delT (p.Cys525AlafsX33) RECQL4
mutation is shared by patients with the three distinct
syndromes, RTS [12], RAPADILINO (one) and BGS
(one). Compound heterozygotes with this and a second
mutation from a large panel have been described among
patients from several ethnic backgrounds
[5,9,13,30,76,79,87-90](Additional file 1) indicating
spreading of the haplotype on which c.1573delT had
occurred. An associated SNP c.1568G>C, signalled in
three RTS patients [30,89,90] and possibly overlooked
by other studies, may be a part of the founder haplo-
type, probably Caucasian according to the ethnicity of
the described RTS patients. No homozygous patient has
been ever detected, raising the suspicion that this trun-
cating mutation may have severe consequences. Indeed,
we know by transcript analysis that the c.1573del T
allele is not transcribed [30].
The second recurrent mutation shown on the world
map (Fig. 4) is exon 14 nonsense c.2269C>T (p.
Gln757X), which is shared by RTS and RAPADILINO.
As in the above cases, this mutation is also widely dis-
tributed and, with a single exception, is found together
with a large number of different mutations in patients
of different ethnicity [5,9,16,76,87,88] (Additional file 1).
Two additional mutations, exon 15 c.2476C>T (p.
Arg826X) and intron 12 splicing c.2059-1G>T, the latter
possibly enhanced by the contiguous unstable minisatel-
lite [86], are found in both RTS and RAPADILINO.
The third recurrent mutation is the Finnish-specific
intron 7 c.1390+2delT, mostly present in a homozygous
state [76,91] (Additional file 1). So far, this splicing
mutation has been detected only in RAPADILINO
patients. The mutation is one of the Fin-major muta-
tions (with a frequency in the Finnish population of 1/
137 [76], with a prevalent founder mutation as the main
contributor due to the population history of this very
isolated country. With the exception of this, the promis-
cuity of RECQL4 mutations is remarkable. However, the
combination of two different mutations appears to be
critical for the determination of one of the three
RECQL4 syndromes. Indeed, RTS and RAPADILINO or
BGS patients have been found to share only one of the
two mutations. This observation suggests that mutant
RECQL4 alleles are primary determinants of the pheno-
type. However, there is the single exception of one RTS
and one BGS patient who share both the earlier men-
tioned exon 9 nonsense c.1573del T p.Cys525AlafsX33
and the exon 18 missense p.Arg1021Trp mutations
[79,90]. Due to the wide clinical expressivity of the
RECQL4 syndromes, patients with the same genotype at
Figure 3 Map of known mutations in the RECQL4 gene (exons are indicated by boxes and introns by interconnecting lines) in RTS
(black), RAPADILINO (purple) and BGS (blue) patients. Yellow identifies the exons encoding the helicase domain. Intronic deletions and
splice site mutations are grouped above, while frameshift, missense and stop mutations are grouped below the graphic representation of the
gene. Bold characters indicate mutations shared by RTS and RAPADILINO (#), RTS and BGS (*) and by RTS, RAPADILINO and BGS (framed).
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the RECQL4 locus should be clinically re-evaluated to
confirm their different clinical diagnoses. Such patients,
and novel similar ones, might be a valuable resource to
search for SNP-array genotyping variants acting as mod-
ulators of the phenotype.
Genotype-phenotype correlations
A general view of the mutations underlying RTS pre-
dicts the expression of low levels of a truncated protein
that lacks either the entire or a part of the helicase
region. The complete loss of RECQL4 function is lethal
in humans and all known mutant proteins found in
patients are partially active [56]. This is due to the pre-
sence of the region near the N-terminus of the protein
homologous to the proteins Sld2 in S. cerevisiae and
DRC1 in S. pombe, which are necessary components for
the initiation of DNA replication [64]. Localisation of
nuclear localisation and retention activities to the
RECQL4 amino-terminus would provide nuclear trans-
port of putative truncated proteins encoded by RTS
mutant alleles [60]. It thus remains possible that all RTS
cell lines have residual RECQL4 activity. In keeping with
this view, only two mutations have been detected
upstream of exon 5: intron 1 c.84+6del16 and intron 2
c.118+27del25, both lead to mis-splicing and both are
present in compound heterozygous patients (Fig. 3).
Moreover, a deletion of the entire gene has never been
identified. Mouse models also indicate that the N-term-
inal domain of RECLQ4 is crucial for cell growth. Mice
with targeted disruption of recql4 exons 5-8 (corre-
sponding to the N-terminus region upstream of the heli-
case domain) die between day 3.5 and 6.5 [66]. By
contrast, mice with either a hypomorphic mutation,
which deletes the single exon 13 [67] or a more exten-
sive region of exons 9-13 [68], are viable and recapitu-
late the clinical symptoms of human RECQL4 diseases.
In both cases, the mutant alleles express aberrant tran-
scripts that could potentially be translated into defective
Recql4 polypeptides, a situation similar to many mutant
alleles identified in RTS II. The knockout mice of Hoki
had a 5% survival rate by the age of two weeks and the
survivors displayed severe growth retardation, bone
defects and impeded cell division [67]. The low bone
mass phenotype in these Recql4-/- and in the surrogate
heterozygous Recql4 +/- mice appears to be associated
with defects in osteoblast progenitors [92]. Parallel find-
ings on control adult mouse bone that show Recql4 pro-
tein localisation in active osteoblasts around the growth
plate but not in fully differentiated osteocytes, indicate
that Recql4 has a function in the regulation of osteopro-
genitor proliferation. Impairment of this cellular
mechanism could underlie the skeletal anomalies
Figure 4 Geographic distribution of recurrent mutations.
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common to all three defective RECQL4 syndromes [92].
Mice with deletion of the Recql4 helicase domain also
show congenital skeletal defects, a distinctive skin
abnormality and increased cancer susceptibility in a sen-
sitised genetic background [68]. Interestingly, fibroblasts
from the viable Recql4 mutant mouse lacking a func-
tional helicase domain were found to display chromoso-
mal instability, aneuploidy, a high frequency of
spontaneous micronuclei and premature chromosome
separation. This shows that a cohesion defect contri-
butes to chromosomal instability [68]. The overall
results from the three knockout models reveal that
these mice present with a spectrum of signs that mimic
the situation in humans, where different mutations in
the RECQL4 gene lead to different phenotypes. Recent
biochemical clues show that each of the two distinct
regions of the protein, the conserved helicase motif and
the Sld2-like-N-terminal domain, independently pro-
motes ATP-dependent unwinding [59]. This, together
with genetic studies in human RTS patients and in
mouse models, demonstrates that RECQL4 is a multi-
functional protein and each specific function may
require different domains. Data on transcript analysis
and on RECQL4 mutant proteins obtained by using
antibodies specific for the N- and C-terminus would
permit validation of the view that disruption of different
regions of the RECQL4 protein affects different aspects
of normal development and genome stability. Genotype-
phenotype correlations by which the combination of
two RECQL4 gene mutations can predict the phenome
of the three RECQL4 syndromes should be addressed.
Life expectancy is not impaired in RTS patients if they
do not develop cancer. Thus, the most important geno-
type-phenotype correlation in RTS patients relates to
the increased risk of cancer, especially osteosarcoma,
which was thought to be determined by the presence of
at least one truncating mutation [5]. Consistent with
this assumption, the most common mutation in RAPA-
DILINO syndrome, an exon 7 in-frame deletion that
spares the helicase region, was found in patients without
malignancies [76]. However, prolonged follow-up of
RAPADILINO patients has revealed cancer in a few
homozygous individuals, as well as in heterozygous car-
riers of this founder mutation [81]. Interestingly, green
fluorescent protein-tagged constructs deleted for exon 7
show a cytoplasmic rather than a nuclear location, thus
mapping the RECQL4 import domain to this region
[60]. Recently a patient with BGS carrying two RECQL4
mutations in exon 15 was reported to develop a midline
NK/T-cell lymphoma [82]. In keeping with these find-
ings, an increased risk of cancer may be predicted for
patients with RECQL4 mutations belonging to all
RECQL4 syndromes. All RECQL4-negative RTS patients
are not at an increased risk of cancer.
Diagnosis
Due to the relatively non-specific nature of the symp-
toms, clinical diagnostic criteria and a score to establish
a “definite”, “probable” or “possible” diagnosis of RTS
are not available. RTS is a disorder with onset in child-
hood and clinical diagnosis is currently based on the
time of onset, spreading and the appearance of poikilo-
derma. According to Wang and Plon [8], diagnosis of
probable RTS can be made if the rash is atypical and if
two of the following clinical signs are present: sparse
hair on the scalp, eyebrows and eyelashes, short stature
and congenital bone defects (including subtle anomalies
that are visible only on X-rays), dental and nail abnorm-
alities, hyperkeratosis, cataracts, and cancers.
The diagnosis of RTS should be considered in all
patients with osteogenic sarcoma, particularly if asso-
ciated with skin changes [9]. The currently available
molecular diagnosis, possibly combining different meth-
ods for analysing the RECQL4 gene should be made
available to patients with typical poikiloderma and addi-
tional signs. Patients with a clinical presentation at the
interface of two distinct RECQL4 syndromes [26,82,90]
should also be tested for RECQL4.
The RECQL4 test is also recommended for RTS cases
that share clinical signs with syndromes usually consid-
ered in the differential diagnosis either because of der-
matological abnormalities or because they belong to the
group of DNA repair disorders with chromosomal
instability (see below).
Only two thirds of patients with a clinical diagnosis of
RTS carry RECQL4 mutations. So far, no other gene has
been detected that can account for the RTS patients
without RECQL4 mutations. RECQL4-negative patients
currently include a clinically and genetically heteroge-
neous group with RTSI patients, who like the RTSII,
have poikiloderma but often display juvenile cataracts,
and other RTS patients with atypical, borderline or
unique phenotypic presentations.
Differential diagnosis
The diagnosis of RTS can be difficult. Several cases have
been identified only after they had developed cancer,
especially osteosarcoma [50]. The onset of osteosarcoma
in a young patient should raise the suspicion of a cancer
predisposition syndrome such as retinoblastoma, Li-
Fraumeni, Werner (see below) and RTS syndrome. In
the absence of cancer, especially when other clinical
signs are missing, the differential diagnosis begins with a
dermatological examination and, if a chronic phase is
established, the following causes of childhood poikilo-
derma should be taken in account [8,92,93].
• Acrogeria (Gottron syndrome), a premature skin
aging syndrome, characterised by poikiloderma and
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lipoatrophy which affects mainly the distal extremi-
ties and manifests itself at birth or shortly after-
wards. The skin becomes dry, thin, transparent and
wrinkled, is easily bruised and exhibits telangiectasia.
Hair and eyes are normal. Small stature has been
reported in several patients.
• Hereditary sclerosing poikiloderma (AD), the
main signs of which are a generalised poikiloderma
appearing in childhood, with accentuation in flexural
areas and on extensor surfaces and sclerodermatous
plaques on palms and soles.
• Dyskeratosis congenita (XR, AD or AR) charac-
terised by the triad: abnormal skin pigmentation
(89% of patients), nail dystrophy (88%) and leukopla-
kia (78%). Skin changes are characterised by reticu-
lated hyperpigmentation or hypopigmentation on the
face, the neck, the trunk, and the thighs. The onset
of poikiloderma and other clinical manifestations
occurs generally during childhood, though later than
in RTS. Severe nail involvement is the initial feature,
which is followed by poikiloderma. Defective denti-
tion and mental retardation are more commonly
noted than in RTS. There is no photosensitivity.
About 80-90% of patients develop bone marrow
abnormalities by the age of 30.
• Kindler’s syndrome (bullous acrokeratotic poikilo-
derma) (AR), is a hereditary bullous poikiloderma
syndrome, where poikiloderma arises generally at the
age of 2-3 years. Chronic trauma-induced blistering
and photosensitivity, which usually start in early
infancy, develop further. Indeed, the patients typi-
cally show acral bullae, which are present at birth or
develop during the first few days of life, with an
onset often resembling epidermolysis bullosa. The
trauma-induced blistering and photosensitivity of
early infancy improve with age giving place to poiki-
loderma, more prominent on the face and neck, and
involving sun-exposed and non-sun-exposed skin,
while skin atrophy is diffuse. Additional features
include stenosis of the oesophagus, anus and ure-
thra, webbing of digits, ectropion and chronic
inflammation of oral mucosa, dental abnormalities
and anhidrosis. A few of these signs may also be
found in RTS patients.
• Xeroderma pigmentosum (AR), an accelerated
photo-aging syndrome, with clinical signs limited to
UV-exposed skin/tissue. Acute sun sensitivity from
early infancy, characterised by severe sunburn with
blistering or persistent erythema after minimal sun
exposure, affects 50% of the patients. Numerous
freckle-like hyperpigmented macules appear on sun-
exposed skin in all individuals, and typically, when
present on the face of a child before age two years,
represent the hallmark of the disease. These
abnormalities evolve into poikilodermatous changes
in late childhood and give a greater than 1000-fold
increased risk of cutaneous skin cancer. Ophthalmo-
logic abnormalities are as frequent as cutaneous
findings and are usually limited to the UV-exposed
portion of the eyes: conjunctiva, cornea, and lids (no
congenital cataract). Other signs include neurologic
abnormalities (30% of patients).
• Clericuzio type Poikiloderma with Neutropaenia
(PN) (AR). Poikiloderma on the face and limbs
(starting in infancy) and short stature are features in
common with RTS. However, unlike in RTS, the
poikiloderma spreads from a rash arising on the dis-
tal limbs to the rest of the body, without sparing the
flexural areas and trunk. Other particular signs of
Clericuzio Poikiloderma are neutropaenia causing
recurrent, especially pulmonary, infections, and pro-
nounced hyperkeratotic nails, especially of the toes.
No photo or heat sensitivity has been reported
[94,95]. The gene for Clericuzio type Poikiloderma
with Neutropenia (PN) has been recently identified
[96], confirming the distinct genetic control of PN
and RTS.
• Exocrine pancreatic hypofunction and atrophy
of the pancreas have been recently described in a
20-year-old male with many clinical features of RTS,
but no mutation in the RECQL4 gene [97]. Due to
marked blister formation, the initial differential diag-
nosis included epidermolysis bullosa (EB) and Kind-
ler syndrome (KS). The authors considered this case
to be a peculiar variant of RTS.
Other rare genodermatoses, with prominent telan-
giectasias but not true poikiloderma, also need to be
differentiated from RTS. They comprise a panel of
DNA repair defects, in particular Bloom’s syndrome
and Werner syndrome, which are caused by defects
in two other RECQ helicases and are also charac-
terised by chromosomal instability.
• Bloom’s syndrome (AR) is characterised by skin
lesions (patchy areas of hypo- or hyperpigmentation)
that are caused by chronic exposure to the sun. These
develop from a red sun-sensitive telangiectatic
erythema, which appears during the first or second
year of life, into a “butterfly distribution” on the face
(similar to lupus erythematosus) and sometimes on
the dorsa of the hands and forearms. However, the
hallmark of the syndrome is the consistent proportion-
ate pre- and postnatal growth retardation accompanied
by dolichocephaly, and predisposition to a wide variety
of malignancies. Recurrent infections (otitis media and
pneumonia), chronic pulmonary disease, diabetes mel-
litus and learning disabilities are common.
• Werner syndrome (AR) has a few clinical features
of premature aging in common with RTS. Werner
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syndrome is also known as segmental progeria of the
adult, as the cardinal signs (i.e. bilateral cataracts,
short stature, premature greying, a “bird-like” facies
and skin changes) appear after the age of ten. Skin
changes include scleroderma-like lesions on acral
areas, with mottled hyperpigmentation, telangiecta-
sias, subcutaneous calcification and ulceration.
Increased risk of mesenchymal cancer, OS included,
has been recorded.
• Fanconi anemia (AR) presents with skin pigmen-
tary changes occurring in 55% of the patients, char-
acterised by generalised, dusky, olive-brown
pigmentation that is most intense on the lower part
of the trunk, in the flexures, and on the neck (85%
of patients) [17]. Short stature (51%) and upper limb
malformations (43%) are signs in common with RTS.
Pancytopaenia typically presents in the first decade.
Malformations of the eyes, kidneys and urinary tract,
ear, heart, gastrointestinal system, oral cavity, and
central nervous system may be present. The patients
may also suffer from hearing loss, hypogonadism
and developmental delay.
• Ataxia-telangiectasia (AR) patients show a combi-
nation of progressive cerebellar ataxia, severe com-
bined immunodeficiency (affecting mainly the
humoral immune response) and oculocutaneous tel-
angiectasia. Onset, related to ataxia, usually occurs
first when the child begins to walk. Cutaneomucosal
telangiectasias, which become apparent between the
ages of 3 and 7 years, are first seen on the face.
These then extend to the neck, the dorsa of the
hands and feet, and to the antecubital and popliteal
areas. Growth delay is also relatively frequent. Can-
cer predisposition, particularly to leukaemia and
Hodgkin’s lymphoma, has been noted.
• Cockayne syndrome patients develop a photodis-
tributed erythema, atrophy, and hyperpigmentation.
They may simulate RTS, but later develop typical
facies, limb abnormalities, wasting and neurological
manifestations between the ages of 1 and 2 years.
Diagnosis is based on clinical findings: poikiloderma,
dwarfism, mental retardation, pigmentary retinopa-
thy, blindness and conduction hearing loss.
Molecular diagnosis and genetic counselling
Molecular diagnosis is currently the only tool available
to a subgroup of RTS patients that can provide them
with a basis for adequate genetic counselling, and parti-
cularly a recommendation for cancer surveillance for
those cases in whom RST II has been confirmed by a
molecular test.
The RECQL4 scan is a complex procedure due to the
need of both DNA and RNA to combine genomic PCR
sequencing with RT-PCR methods, which detect splicing
and other unique mutations common in RTS. Using
RNA analysis, we have identified a homozygous 11 bp
deletion in intron 8, which results in intron retention,
frameshift and premature termination, and which would
not have been detected by standard genomic PCR
sequencing [84]. It is worth noting that nearly one third
of all the identified RECQL4 mutations are splicing
mutations (Fig. 3), often not canonical, i.e. escaping
detection by standard genomic analysis. In all cases in
which we were able to analyse the transcripts, valuable
information on the type of mutation and predicted effect
could be obtained [26,30]. Combined western blots
using a C-terminal and a N-terminal antibody are war-
ranted in order to detect whether or not truncated pro-
teins are produced and to translate this information into
clinical management of the patients.
RTS is an autosomal recessive genetic disease. There-
fore, patients with a consistent diagnosis of RTS, along
with their parents and siblings, should be referred for
genetic counselling to ensure early identification and
treatment of syndrome-associated manifestations. Spe-
cial attention is needed for cancer surveillance. Con-
struction of the family tree allows the identification of
parental consanguinity (third cousins or closer) and of
family members who may be affected or at risk of being
carriers of a RECQL4 mutation.
As with all recessive conditions, both parents of the
proband are obligate heterozygotes for a disease-causing
mutation. The siblings have a 25% chance of being
affected, a 50% chance of being asymptomatic carriers
and a 25% chance of being non-carriers.
Heterozygous carriers of a RECQL4 mutation are
asymptomatic.
Cytogenetic studies and chromosomal instability
It has been noted that chromosomal instability of RecQ
helicase mutant cells is a secondary manifestation of pri-
mary defects in replication and repair functions [55].
Difficulties in establishing whether this cellular pheno-
type might be a useful adjunct to clinical diagnosis are
due to: i) the description of chromosomal instability in
RTS patients before the RECQL4 molecular test became
available, making uncertain in these cases the relation-
ship of the observed phenomenon with RTS caused by
the RECQL4 defect; ii) the variability in the applied pro-
cedure as either spontaneous or induced chromosomal
instability was monitored and iii) the variability in the
cells used for testing, which include lymphocytes, fibro-
blasts and lymphoblastoid cell lines. The lack of a stan-
dardised method accounts for the conflicting literature
data and precludes drawing any standardised guideline
for diagnostic purposes. Yet, a few points can be noted.
Independent of the method and target cell, chromoso-
mal instability, whenever found, appears to be distinctive
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and is mainly represented by mosaic aneuploidies and
isochromosomes [80]. Multiple evidence for in vivo
mosaicism of trisomy 8 and/or 7 and/or 2
[13,19,30,46,98,99] has been found, even in the absence
of increased spontaneous chromosomal instability [27].
Among structural chromosomal abnormalities, isochro-
mosomes (mainly of the same chromosomes that were
found to be trisomic, namely 8, 7 and 2) have been fre-
quently observed and appear to be quite characteristic
for this syndrome [13,19,30,99,100]. Mouse embryonic
fibroblasts have confirmed this chromosomal instability
pattern displaying an overall aneuploid phenotype and a
significant increase in premature centromere separation
[68]. This latter sign shows a failure of correctly segre-
gating sister chromatids [61]. This may reflect the action
of RECQL4 in the N-end rule pathway [57]. While the
frequency of breaks was generally normal on lympho-
cytes from tested RTS cases [13,27,46,98], with a few
exceptions [30,101], multiple spontaneous breaks have
been observed on skin fibroblasts [6,35,46]. In vivo,
chromosomal instability may drive neoplastic transfor-
mation of cancer stem/progenitor cells that are espe-
cially sensitive to the effect of RECQL4 mutations. This
may be true for cells of the mesenchymal compartment
that give rise to the tumours most frequently developed
by RTS patients. At the level of the organism, chromo-
somal instability is an epiphenomenon, primed by the
multiple defective RECQL4 functions and possibly
modulated by the nature and combination of the two
RECQL4 mutations. At the somatic level, however, it is
(together with the RECQL4 point mutation) a powerful
co-instigator of tumourigenesis.
As compared to chromosomal instability features of
other RECQ helicase defects, RTS has apparently no
overlap with Bloom’s syndrome. No increase in sister
chromatid exchanges (SCEs), which is the characteristic
sign of Bloom cells, has been recorded in RTS cells
[14,27,89]. RTS resembles Werner syndrome with
respect to a few clinical features and the increased pre-
disposition to mesenchymal tumours. However, the
spectrum of chromosomal rearrangements appears more
restricted in RTS than in Werner cells where the “varie-
gated translocation mosaicism” is enhanced by multiple
pathways, including telomere erosion and chromosome
end fusions [56]. On the other hand, numerical CIN is
typical of RTS and, as in the mosaic variegated aneu-
ploidy syndrome [102], indicates a failure in the mitotic
spindle checkpoint.
Sensitivity of RTS cells to genotoxic agents
Normal results of nucleotide excision repair study, as
measured by the functional unscheduled DNA synthesis
assay, were found on RTS lymphocytes with an
unknown [27] or known RECQL4 mutational status [35].
Conflicting results have been obtained on the sensitiv-
ity of RTS cells to UV irradiation [6]. These showed
either decreased DNA repair [103,104] or a normal
response [4,16,27,105]. Inconsistencies were also found
among studies of the response to ionizing radiation (IR)
[4,106], possibly because of the use of different experi-
mental systems, fibroblasts or lymphocytes, and due to
lack of information on the RECQL4 status. This may
explain part of the heterogeneity of the syndrome. A
more recent study on Recql4 KO mouse embryonic
fibroblasts using the colony survival assay demonstrated
normal sensitivity to both UV and IR [67]. The same
result was obtained using a cytotoxicity survival test on
human RECQL4-deficient fibroblasts [16]. Cultured lym-
phocytes from a patient and her mother exposed to
mitomycin C and diepoxybutane did not show increased
sensitivity to the dialkylating agents [27]. However, a
defect in S phase arrest was found in human RECQL4-
deficient fibroblasts using FACS (Fluorescent Activated
Cell Sorter) analysis [107]. Only recently, a systematic
study on the sensitivity to genotoxic agents of primary
fibroblasts from 10 RTS patients carrying two deleter-
ious RECQL4 mutations has been carried out using the
colony survival assay [108]. Results show increased sen-
sitivity to agents that interfere with DNA replication,
such as hydroxyurea, camptothecin and the anticancer
agent doxorubicin, in line with the role of RECQL4 heli-
case in DNA replication [55,64]. The same study
demonstrated modest sensitivity to agents such as UV
and IR and cisplatin that predominantly cause damage
that requires DSB repair or nucleotide excision repair
mechanisms (NER). Another study showed no sensitivity
of primary RECQL4-deficient fibroblasts to any of the
above mentioned genotoxic agents nor to agents such as
hydrogen peroxide which induces oxidative DNA
damage via reactive oxygen species [16], in contrast to
previous findings [74]. How can one reconcile these
results with the implication of the multifunctional
RECQL4 protein in the repair of exogenous damage by
homologous recombination [69,70], NER [75] and
response to oxidative stress [73,74]? The knowledge of
the molecular mechanisms underlying the differences in
response of RECQL4-deficient cells to different geno-
toxic agents will provide clear-cut answers.
Management and treatment
Patients should be managed by a multidisciplinary team,
which includes a dermatologist, an ophthalmologist, an
orthopaedic surgeon and an oncologist. All RTS patients
should be offered long term follow-up.
Treatment includes the use of pulsed dye laser photo-
coagulation to improve the telangiectatic component of
the rash [109], surgical removal of the cataracts and
standard treatment for affected individuals who develop
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cancer. Surveillance includes annual physical examina-
tion by clinicians aware of the natural history and the
need for precise long-term follow-up, including careful
osteoarticular monitoring for detection of a bone
tumour, skin monitoring for lesions with unusual colour
or texture and eye examination.
RTS can be considered among the systemic diseases
associated with early-onset periodontitis. In the absence
of other common secondary features of the syndrome,
dental radiographic screening is recommended in the
diagnostic work-up of suspected patients. Short root
anomaly (rhizomicry) has been associated with an
increased tendency to root resorption: thus all factors
capable of enhancing further loss of the apical structure
of the affected teeth, ranging from masticatory stress,
fixed prostheses, caries or periodontal disease, should be
avoided [18].
In RTS patients with respiratory symptoms, pulmon-
ary function tests and computed tomography should be
considered in the further work-up for bronchitis and
bronchiectasis [35].
At diagnosis a skeletal survey of the long bones at
infancy has been recommended since underlying skeletal
dysplasia may impair subsequent diagnosis of osteogenic
sarcoma [19]. It is also recommended to perform com-
plete dermatologic screening for cutaneous tumours and
to advise patients to use sunscreens.
A debatable issue is the potential risk of radiation
exposure from radiologic screening for osteosarcoma in
RECQL4 mutation-positive RTS patients. Data on mod-
est sensitivity of RECQL4-deficient fibroblasts to DNA
damaging agents (including UV and ionizing radiation
[108] do not argue for or against screening. A study on
the response to therapy of osteosarcoma in patients
with RTS indicated that these patients, even if affected
by a chromosomal instability disorder, just as patients
with Ataxia-telangiectasia, Fanconi anaemia and xero-
derma pigmentosum, do not present the same level of
sensitivity to genotoxic agents. For this reason they
should be treated initially with conventional doses.
However, caution and careful clinical observation is war-
ranted for monitoring for enhanced doxorubicin sensi-
tivity and side effects in the form of mucositis in RTS
patients [50]. By contrast, cisplatin (to which RECQL4-
deficient fibroblasts are less sensitive [108] can replace
doxorubicin as an active chemotherapy agent as it has
been shown to cause no apparent increased toxicity [50].
Successful umbilical cord blood stem cell transplanta-
tion has been performed in one patient with RTS and
combined immunodeficiency [85], while an allogenic
bone marrow transplantation has been carried out in
another case of RTS with myelodysplastic syndrome
[36].
Prognosis
Although some clinical signs suggest precocious aging,
the patients’ lifespan is not altered, provided that the
neoplastic disease is diagnosed and treated in time.
The histological response of the OS lesions to stan-
dard chemotherapy and the clinical outcome in the pre-
sence of OS are similar in RTS and non-RTS patients,
with a five-year survival rate of 60-70% [50].
Conclusions and perspectives
One main question that remains open is whether the
clinical presentation of RTS as diagnosed by the proto-
typic sign, i.e. poikiloderma, might raise in itself a
dichotomy between juvenile cataract and radial ray
defects, which would lead to splitting of the syndrome
in different subsets with a distinct genetic control. So
far, the RECQL4 locus has been clearly associated with
skeletal defects and susceptibility to cancer, mainly
osteosarcoma and skin cancer, while the occurrence of
bilateral cataract is not an obligatory sign of RECQL4-
positive patients. Identification of a second locus
accounting for up to one third of clinically diagnosed
RTS cases should confirm the locus heterogeneity of the
syndrome directing the laboratory flow-chart towards
screening of the major RECQL4 mutations or the, as yet
unknown, minor gene(s). However, even if this goal is
reached it is unlikely that the entire clinical expressivity
of RTS would be solved. Among clinical sub-entities
within the wide spectrum of RTS, Clericuzio type poiki-
loderma with neutropaenia has been shown to lack
RECQL4 mutations and has been just recognized to be
genetically distinct from RTS [94-96]. The other less
defined presentations, broadly defined as variant or aty-
pical [22,97], might result from rare combinations of
RECQL4 mutations, which have so far escaped detection
due to technical reasons or due to involvement of novel
genomic or epigenetic mechanisms.
Also, RTS patients who are defined by a positive
RECQL4 test often have been characterised only for one
RECQL4 mutation, with a second mutation being unde-
tectable by the standard mutation scan. A challenging
issue is the genotype-phenotype correlation in RTS
patients: genomic identification of both mutations is
insufficient to predict the consequences of the muta-
tions and should be corroborated by transcript analysis
and the use of antibodies directed towards the N- and
C-terminal parts of the protein. Future studies elucidat-
ing the differences in response of RECQL4-deficient
cells to different genotoxic agents may provide insights
into the comprehension of the molecular basis of RTS.
A full comprehension of the defective cellular pathways
is of upmost relevance to assess the cancer risk of the
affected individuals and to offer them careful
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surveillance. The recent follow-up of RAPADILINO
patients who developed either osteosarcoma or lym-
phoma [81] has changed the view on predisposition to
cancer and cancer types underlined by RECQL4-asso-
ciated diseases. Quite striking in this regard is the just
reported finding of the first out of 24 described patients
with BGS who developed a NK/T-cell lymphoma [82].
Sharing of both mutations by patients with distinct syn-
dromes of the RECQL4 spectrum may be more frequent
than has been shown thus far and such situations may
pave the way to the discovery of modifier genes. Other
open questions are the putative cancer risk of unaffected
carriers of a RECQL4 mutant allele and the involvement
of somatic RECQL4 mutations in sporadic osteosarcoma,
in spite of the fact that this possibility has been
excluded by the only study which has so far addressed
the issue [110].
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